Hemostasis Today

June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Jan T. Kielstein: Bleeding Risk Outweighs Potential Benefits of Rivaroxaban in CKD Patients
Jun 5, 2026, 14:44

Jan T. Kielstein: Bleeding Risk Outweighs Potential Benefits of Rivaroxaban in CKD Patients

Jan T. Kielstein, Director of Braunschweig Municipal Medical Center, shared a post on LinkedIn about a recent article by Sunil V. Badve, published in JAMA, adding:

“Despite COMPASS off TRACK LBCT at ERA26.

While COMPASS showed a decrease of stroke and cardiovascular mortality under twice daily low dose rivaroxaban the same approach in patients with advanced CKD at high cardiovascular risk, low-dose rivaroxaban did not reduce the risk of a composite cardiovascular outcome.

The study was prematurely stopped due to major bleeding rates in the low-dose rivaroxaban group compared with the placebo group.”

Title: Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease

Authors: Sunil V. Badve, Vlado Perkovic, Vivekanand Jha, Raja Ramachandran, Lily Mushahar, Jan Menne, An S. De Vriese, Patrick Rossignol, Adrien Flahault, Maha Al Ammari, Habib Skhiri, Michael Walsh, David Collister, Adrian Liew, Laurent Billot, Severine Bompoint, Anthony Devaux, Min Jun, Enmoore Lin, Aline Ramos da Cruz, Jeffrey T. Ha, John W. Eikelboom, Ahmed Shaman, Meg J. Jardine, Shilpanjali Jesudason, Muh Geot Wong, Craig S. Anderson, Amit X. Garg, Hiddo J. L. Heerspink, Helen Monaghan, Anushka Patel, Patrick B. Mark, David C. Wheeler, Jicheng Lv, Li Zuo, Helen Pilmore, Martin Gallagher

Jan T. Kielstein: Bleeding Risk Outweighs Potential Benefits of Rivaroxaban in CKD Patients

Stay updated on all scientific advances with Hemostasis Today.